Antiplatelet therapy: present status and future prospects

Bibliography

• FURIE B, FURIE BC: Thrombus formation in vivo. J. Clin. Invest. (2005) 115(12):3355-3362.
   PubMed Web of Science ®Google Scholar
• BRASS LF: Thrombus formation: stability matters. Blood (2006) 108(9):2883-2884.
   Web of Science ®Google Scholar
• SAVAGE B, SALDIVAR E, RUGGERI ZM: Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell (1996) 84(2):289-297.
   PubMed Web of Science ®Google Scholar
• KATO K, KANAJI T, RUSSELL S et al.: The contribution of glycoprotein VI to stable platelet adhesion and thrombus formation illustrated by targeted gene deletion. Blood (2003) 102:1701-1707.
   PubMed Web of Science ®Google Scholar
• JACKSON SP: The growing complexity of platelet aggregation. Blood (2007).
   Google Scholar
• DENIS CV, WAGNER DD: Platelet adhesion receptors and their ligands in mouse models of thrombosis. Arterioscler. Thromb. Vasc. Biol. (2007) 27(4):728-739.
   PubMed Web of Science ®Google Scholar
• BRASS LF, JIANG H, WU J, STALKER TJ, ZHU L: Contact-dependent signaling events that promote thrombus formation. Blood Cells Mol. Dis. (2006) 36(2):157-161.
   PubMed Web of Science ®Google Scholar
• EIDELMAN RS, HEBERT PR, WEISMAN SM, HENNEKENS CH: An update on aspirin in the primary prevention of cardiovascular disease. Arch. Intern. Med. (2003) 163(17):2006-2010.
   PubMed Web of Science ®Google Scholar
• RIDKER PM, COOK NR, LEE IM et al.: A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. (2005) 352(13):1293-1304.
   PubMed Web of Science ®Google Scholar
• HENNEKENS CH, KNATTERUD GL, PFEFFER MA: Use of aspirin to reduce risks of cardiovascular disease in patients with diabetes: clinical and research challenges. Diabetes Care (2004) 27(11):2752-2754.
   PubMed Web of Science ®Google Scholar
• ANTITHROMBOTIC TRIALISTS' COLLABORATION: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ (2002) 324(7329):71-86.
   PubMed Web of Science ®Google Scholar
• GUM PA, KOTTKE-MARCHANT K, WELSH PA, WHITE J, TOPOL EJ: A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J. Am. Coll. Cardiol. (2003) 41(6):961-965.
   PubMed Web of Science ®Google Scholar
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet (1996) 348(9038):1329-1339.
   PubMed Web of Science ®Google Scholar
• SABATINE MS, CANNON CP, GIBSON CM et al.: Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. (2005) 352(12):1179-1189.
   PubMed Web of Science ®Google Scholar
• YUSUF S, ZHAO F, MEHTA SR et al.: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. (2001) 345(7):494-502.
   PubMed Web of Science ®Google Scholar
• BHATT DL, FOX KA, HACKE W et al.: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. (2006) 354(16):1706-1717.
   PubMed Web of Science ®Google Scholar
• GURBEL PA, BLIDEN KP, HIATT BL, O'CONNOR CM: Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation (2003) 107(23):2908-2913.
   PubMed Web of Science ®Google Scholar
• SCHAEFER WM, KOCH KC, NOWAK B et al.: Dipyridamole/aspirin combination in secondary stroke prevention: effects on absolute myocardial blood flow and coronary vascular resistance. Int. J. Clin. Pharmacol. Ther. (2006) 44(7):319-325.
   PubMed Web of Science ®Google Scholar
• KARVOUNI E, KATRITSIS DG, IOANNIDIS JP: Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J. Am. Coll. Cardiol. (2003) 41(1):26-32.
   PubMed Web of Science ®Google Scholar
• CHEW DP, BHATT DL, SAPP S, TOPOL EJ: Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of Phase III multicenter randomized trials. Circulation (2001) 103(2):201-206.
   PubMed Web of Science ®Google Scholar
• CAUWENBERGHS N, MEIRING M, VAUTERIN S et al.: Antithrombotic effect of platelet glycoprotein Ib-blocking monoclonal antibody Fab fragments in nonhuman primates. Arterioscler. Thromb. Vasc. Biol. (2000) 20(5):1347-1353.
   PubMed Web of Science ®Google Scholar
• MANGIN P, YAP CL, NONNE C et al.: Thrombin overcomes the thrombosis defect associated with platelet GPVI/FcRγ deficiency. Blood (2006) 107(11):4346-4353.
   PubMed Web of Science ®Google Scholar
• DUBOIS C, PANICOT-DUBOIS L, GAINOR JF, FURIE BC, FURIE B: Thrombin-initiated platelet activation in vivo is vWF independent during thrombus formation in a laser injury model. J. Clin. Invest. (2007) 117(4):953-960.
   PubMed Web of Science ®Google Scholar
• LEON C, HECHLER B, FREUND M et al.: Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice. J. Clin. Invest. (1999) 104(12):1731-1737.
   PubMed Web of Science ®Google Scholar
• HECHLER B, NONNE C, ROH EJ et al.: MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2′-deoxyadenosine-3′, 5′-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice. J. Pharmacol. Exp. Ther. (2006) 316(2):556-563.
   PubMed Web of Science ®Google Scholar
• WEISS EJ, HAMILTON JR, LEASE KE, COUGHLIN SR: Protection against thrombosis in mice lacking PAR3. Blood (2002) 100(9):3240-3244.
   PubMed Web of Science ®Google Scholar
• COOK JJ, SITKO GR, BEDNAR B et al.: An antibody against the cloned thrombin receptor inhibits experimental arterial thrombosis in the African green monkey. Circulation (1995) 91:2961-2971.
   PubMed Web of Science ®Google Scholar
• DERIAN CK, DAMIANO BP, ADDO MF et al.: Blockade of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J. Pharmacol. Exp. Ther. (2003) 304(2):855-861.
   PubMed Web of Science ®Google Scholar
• THOMAS DW, MANNON RB, MANNON PJ et al.: Coagulation defects and altered hemodynamic responses in mice lacking receptors for thromboxane A2. J. Clin. Invest. (1998) 102(11):1994-2001.
   PubMed Web of Science ®Google Scholar
• HIRATA T, KAKIZUKA A, USHIKUBI F et al.: Arg60 to Leu mutation of the human thromboxane A2 receptor in a dominantly inherited bleeding disorder. J. Clin. Invest. (1994) 94(4):1662-1667.
   PubMed Web of Science ®Google Scholar
• ANDRE P, PRASAD KS, DENIS CV et al.: CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanism. Nat. Med. (2002) 8(3):247-252.
   PubMed Web of Science ®Google Scholar
• PREVOST N, WOULFE DS, JIANG H et al.: Eph kinases and ephrins support thrombus growth and stability by regulating integrin outside-in signaling in platelets. Proc. Natl. Acad. Sci. USA (2005) 102(28):9820-9825.
   PubMed Web of Science ®Google Scholar
• ANGELILLO-SCHERRER A, DE FRUTOS P, APARICIO C et al.: Deficiency or inhibition of Gas6 causes platelet dysfunction and protects mice against thrombosis. Nat. Med. (2001) 7(2):215-221.
   PubMed Web of Science ®Google Scholar
• OBERGFELL A, JUDD BA, DEL POZO MA et al.: The molecular adapter SLP-76 relays signals from platelet integrin αIIbβ3 to the actin cytoskeleton. J. Biol. Chem. (2001) 276(8):5916-5923.
   PubMed Web of Science ®Google Scholar
• NANDA N, ANDRE P, BAO M et al.: Platelet aggregation induces platelet aggregate stability via SLAM family receptor signaling. Blood (2005) 106(9):3028-3034.
   PubMed Web of Science ®Google Scholar